Cellular and Molecular Signaling Research Group, Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
Cell Immunol. 2011;271(1):5-14. doi: 10.1016/j.cellimm.2011.06.021. Epub 2011 Jun 26.
As fascinating a molecule as it can potentially get, nuclear factor-κB (NF-κB), a regulatory transcription factor, is as intriguing. NF-κB is a dimeric complex that controls the transcription of essential genes. NF-κB is involved in a variety of responses that play a pivotal role in regulating the immune response to inflammation, infection, and nociception. Aberrant regulation of NF-κB has been linked to certain conditions such as cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune responses. Cellular and molecular regulatory mechanisms and pathways involving the regulation of this transcription factor are being unraveled. Therapeutic approaches have emerged underlying the regulatory impact of oligonucleotides/decoys and other non-decoy inhibitors on NF-κB modulation. In this synopsis, we emphasize the role of decoy therapy in understanding the crucial influence of this transcription factor, and further weigh not only the efficacy of this therapeutic approach but also its necessity and contraindications.
尽管核因子-κB(NF-κB)作为一种潜在的分子可能非常有趣,但它作为一种调节转录因子同样引人入胜。NF-κB 是一种二聚体复合物,可控制必需基因的转录。NF-κB 参与多种反应,在调节对炎症、感染和伤害感受的免疫反应中起着关键作用。NF-κB 的异常调节与某些疾病有关,如癌症、炎症性和自身免疫性疾病、感染性休克、病毒感染和免疫反应不当。目前正在揭示涉及该转录因子调节的细胞和分子调节机制和途径。基于寡核苷酸/诱饵和其他非诱饵抑制剂对 NF-κB 调节的调控作用,已经出现了治疗方法。在这篇综述中,我们强调了诱饵治疗在理解这种转录因子的关键影响方面的作用,并进一步不仅权衡了这种治疗方法的疗效,还权衡了其必要性和禁忌症。